Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2023

Genmab — Juli 2023

Planlagt Fastgjort Låst Flyttet Genmab
551 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #115

    Wat do you mean Peter? The fact that the stage IIIb patients were excluded from the first trial?

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #116

      https://www.prnewswire.com/news-releases/treatment-with-rybrevant-amivantamab-vmjw-plus-chemotherapy-resulted-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-egfr-exon-20-insertion-mutati-301878443.html?tc=eml_cleartime Treatment with RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnose

      1 Reply Last reply
      0
      • A Offline
        A Offline
        AaBforever
        wrote on sidst redigeret af
        #117

        Nå...nu ser det da ud til at retningen er UP:-)

        1 Reply Last reply
        0
        • D Offline
          D Offline
          deleted-user
          wrote on sidst redigeret af
          #118

          Ja og snakken om kurs 2450 forstummede. Saxo kører med et muligt bull signal omkring 2950 over 50 dage, hvis wedgen bryde op

          1 Reply Last reply
          0
          • T Offline
            T Offline
            Teller
            wrote on sidst redigeret af
            #119

            Bliver spændende om stigningen kan modnes hen over ugen 🙂

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #120

              Vi kan jo håbe på gode salgstal på torsdag.

              1 Reply Last reply
              0
              • P Offline
                P Offline
                Pensionisten
                wrote on sidst redigeret af
                #121

                Genmab (+2,3%, 2686) parternen Novartis øgede i andet kvartal salget af Kesimpta til 489 mio. dollar. Det svarer til en stigning på 105 pct. sammenlignet med salget i samme kvartal sidste år. Kesimpta til behandling af multipel sklerose er baseret på Genmabs virkemiddel Ofatumumab, og Genmab modtager 10 pct. af salget i royalties. Kilde: Landbobanken Børsnyt

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  ProinvestorNEWS
                  wrote on sidst redigeret af
                  #122

                  Schweizisk Genmab-partner opjusterer efter overbevisende kvartal https://www.proinvestor.com/investornyt/1016615/schweizisk-genmab-partner-opjusterer-efter-overbevisende-kvartal

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #123

                    Mon ikke vi kan nærme os en dobbelt BB i år for Kesimpta - ikke dårligt

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #124

                      Novartis Q2 2023 Results
                      Investor
                      presentation https://www.novartis.com/sites/novartis_com/files/q2-2023-investor-presentation.pdf

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #125

                        Q1: $386 mln, Q2: $489 mln og $873 mln for H123. Vi er vel over BB nu 🙂 https://www.novartis.com/sites/novartis_com/files/q2-2023-media-release-en.pdf side 5

                        1 Reply Last reply
                        0
                        • nohopeN Offline
                          nohopeN Offline
                          nohope
                          wrote on sidst redigeret af
                          #126

                          h

                          1 Reply Last reply
                          0
                          • nohopeN Offline
                            nohopeN Offline
                            nohope
                            wrote on sidst redigeret af
                            #127

                            Han bad om dobbelt BB = 2 MIA

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #128

                              Ok det bliver det også 🙂

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #129

                                Imponerende tempo Novartis har på udrulningen. Mange nye pts på Kesimpta.

                                1 Reply Last reply
                                0
                                • J Offline
                                  J Offline
                                  JKY_VH
                                  wrote on sidst redigeret af
                                  #130

                                  Jep, som at se Vinge på enkeltstarten 😉

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #131

                                    Hvem sagde “kannibalen”?

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JKY_VH
                                      wrote on sidst redigeret af
                                      #132

                                      hehe Bulder;-)

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #133

                                        Novartis Ag (NVS) Q2 2023 Earnings Call Transcript https://www.proinvestor.com/investornyt/1017067/novartis-ag-nvs-q2-2023-earnings-call-transcript

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #134

                                          Godmorgen 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper